share_log
Moomoo 24/7 ·  Mar 8 07:03
Amylyx Pharmaceuticals Announced Topline Results From PHOENIX Phase 3 Trial Of AMX0035 For Amyotrophic Lateral Sclerosis, The Study Did Not Meet Its Primary Endpoint Nor Was There Statistical Significance Seen In Secondary Endpoints
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment